AD-214 effective in gold standard pre-clinical animal model
Filed with ASX · · 3 pages · English
In the deck
Earlier from AdAlta
- Appendix 4C - quarterly
- AdAlta Granted US Patent for AD-214
- AD-214 Phase I strategy and timing update
- AdAlta awarded Biomedical Translation Bridge Funding
- GLP Toxicology study results
Later from AdAlta
- Investor Briefing - Strategic Plan
- Board changes and R&D Tax Incentive advance received
- Business update and COVID-19 response
- AdAlta receives approval to commence AD-214 Phase I trial
- Supportive US FDA pre-IND meeting results for AD-214
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta